Your browser doesn't support javascript.
loading
Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents
Berislav Bošnjak; Saskia Catherina Stein; Stefanie Willenzon; Anne Katrin Cordes; Wolfram Puppe; Günter Bernhardt; Inga Ravens; Christiane Ritter; Christian R Schultze-Florey; Nina Gödecke; Jörg Martens; Hannah Kleine-Weber; Markus Hoffmann; Anne Cossmann; Mustafa Yilmaz; Isabelle Pink; Marius M Hoeper; Georg MN Behrens; Stefan Pöhlmann; Rainer Blasczyk; Thomas F Schulz; Reinhold Förster.
Afiliación
  • Berislav Bošnjak; Hannover Medical School
  • Saskia Catherina Stein; Hannover Medical School
  • Stefanie Willenzon; Hannover Medical School
  • Anne Katrin Cordes; Hannover Medical School
  • Wolfram Puppe; Hannover Medical School
  • Günter Bernhardt; Hannover Medical School
  • Inga Ravens; Hannover Medical School
  • Christiane Ritter; Hannover Medical School
  • Christian R Schultze-Florey; Hannover Medical School
  • Nina Gödecke; Hannover Medical School
  • Jörg Martens; Hannover Medical School
  • Hannah Kleine-Weber; University Göttingen
  • Markus Hoffmann; University Göttingen
  • Anne Cossmann; Hannover Medical School
  • Mustafa Yilmaz; Public Health Department
  • Isabelle Pink; Hannover Medical School
  • Marius M Hoeper; Hannover Medical School
  • Georg MN Behrens; Hannover Medical School
  • Stefan Pöhlmann; University Göttingen
  • Rainer Blasczyk; Hannover Medical School
  • Thomas F Schulz; Hannover Medical School
  • Reinhold Förster; Hannover Medical School
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20151407
ABSTRACT
Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells using surface-expressed angiotensin-converting enzyme 2 (ACE2). We developed a surrogate neutralization test (sVNT) to assess at what degree serum antibodies interfere with the binding of SARS-CoV-2-S-RBD to ACE2. The sVNT revealed neutralizing anti-SARS-CoV-2-S antibodies in the sera of 90% of mildly and 100% of severely affected coronavirus-disease-2019 (COVID-19) convalescent patients. Importantly, sVNT results correlated strongly to the results from pseudotyped-vesicular stomatitis virus-vector-based neutralization assay and to levels of anti-SARS-CoV-2-S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies also correlated to duration and severity of clinical symptoms, but not patient age or gender. These findings together with the sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint